Profund Advisors’s CVS Health CVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.47M Sell
14,213
-3
-0% -$268 0.04% 273
2026
Q1
$1.02M Sell
14,216
-6,435
-31% -$496K 0.04% 343
2025
Q4
$1.64M Buy
20,651
+4,279
+26% +$337K 0.05% 254
2025
Q3
$1.23M Buy
16,372
+217
+1% +$14.9K 0.04% 284
2025
Q2
$1.11M Sell
16,155
-1,093
-6% -$71.7K 0.04% 282
2025
Q1
$1.17M Sell
17,248
-459
-3% -$27.5K 0.05% 267
2024
Q4
$795K Sell
17,707
-3,130
-15% -$176K 0.03% 344
2024
Q3
$1.31M Buy
20,837
+1,756
+9% +$102K 0.05% 263
2024
Q2
$1.13M Sell
19,081
-170
-0.9% -$10.6K 0.04% 270
2024
Q1
$1.54M Sell
19,251
-2,718
-12% -$208K 0.06% 223
2023
Q4
$1.73M Buy
21,969
+2,257
+11% +$161K 0.07% 199
2023
Q3
$1.38M Sell
19,712
-64
-0.3% -$4.54K 0.08% 214
2023
Q2
$1.37M Buy
19,776
+459
+2% +$32.7K 0.07% 237
2023
Q1
$1.44M Sell
19,317
-3,302
-15% -$277K 0.09% 192
2022
Q4
$2.11M Buy
22,619
+2,427
+12% +$234K 0.14% 139
2022
Q3
$1.93M Sell
20,192
-1,494
-7% -$148K 0.14% 135
2022
Q2
$2.01M Sell
21,686
-2,623
-11% -$256K 0.13% 144
2022
Q1
$2.46M Sell
24,309
-2,524
-9% -$265K 0.1% 169
2021
Q4
$2.77M Buy
26,833
+831
+3% +$76.8K 0.09% 168
2021
Q3
$2.21M Buy
26,002
+229
+0.9% +$19.2K 0.07% 211
2021
Q2
$2.15M Buy
25,773
+272
+1% +$22.3K 0.07% 216
2021
Q1
$1.92M Sell
25,501
-1,333
-5% -$97.1K 0.07% 208
2020
Q4
$1.83M Sell
26,834
-475
-2% -$30.9K 0.08% 209
2020
Q3
$1.59M Sell
27,309
-6,638
-20% -$413K 0.08% 204
2020
Q2
$2.21M Buy
33,947
+4,493
+15% +$283K 0.12% 151
2020
Q1
$1.75M Sell
29,454
-7,669
-21% -$512K 0.13% 136
2019
Q4
$2.76M Buy
37,123
+4,398
+13% +$309K 0.12% 146
2019
Q3
$2.06M Sell
32,725
-4,750
-13% -$281K 0.1% 175
2019
Q2
$2.04M Sell
37,475
-7,265
-16% -$391K 0.1% 195
2019
Q1
$2.41M Buy
44,740
+3,738
+9% +$231K 0.12% 162
2018
Q4
$2.69M Buy
41,002
+970
+2% +$72.4K 0.17% 111
2018
Q3
$3.15M Buy
40,032
+10,588
+36% +$757K 0.12% 145
2018
Q2
$1.9M Sell
29,444
-3,610
-11% -$238K 0.08% 215
2018
Q1
$2.06M Sell
33,054
-747
-2% -$53.6K 0.08% 202
2017
Q4
$2.45M Buy
33,801
+6,066
+22% +$441K 0.09% 180
2017
Q3
$2.25M Sell
27,735
-6,376
-19% -$504K 0.09% 190
2017
Q2
$2.75M Buy
34,111
+5,687
+20% +$449K 0.12% 141
2017
Q1
$2.23M Sell
28,424
-10,940
-28% -$873K 0.1% 159
2016
Q4
$3.11M Buy
39,364
+9,116
+30% +$738K 0.14% 109
2016
Q3
$2.69M Sell
30,248
-3,372
-10% -$318K 0.13% 127
2016
Q2
$3.22M Sell
33,620
-4,301
-11% -$429K 0.16% 101
2016
Q1
$3.93M Sell
37,921
-5,478
-13% -$533K 0.2% 77
2015
Q4
$4.24M Buy
43,399
+2,141
+5% +$210K 0.2% 73
2015
Q3
$3.98M Sell
41,258
-15,275
-27% -$1.61M 0.23% 60
2015
Q2
$5.93M Sell
56,533
-2,906
-5% -$297K 0.25% 57
2015
Q1
$6.13M Buy
59,439
+1,803
+3% +$182K 0.24% 60
2014
Q4
$5.55M Buy
57,636
+11,576
+25% +$1.02M 0.23% 70
2014
Q3
$3.67M Buy
46,060
+4,027
+10% +$317K 0.17% 93
2014
Q2
$3.17M Sell
42,033
-2,404
-5% -$182K 0.14% 120
2014
Q1
$3.33M Sell
44,437
-5,171
-10% -$365K 0.15% 93
2013
Q4
$3.55M Buy
49,608
+5,620
+13% +$361K 0.16% 86
2013
Q3
$2.5M Sell
43,988
-1,472
-3% -$87.7K 0.13% 109
2013
Q2
$2.6M Buy
+45,460
New +$2.63M 0.18% 88

Other funds holding CVS

Profund Advisors's CVS Position: Q2 2026 in Review

Profund Advisors reduced its CVS Health (CVS) stake by 0.02% in Q2 2026, selling an estimated $268 and leaving 14,213 shares worth $1.47M. The position accounts for 0.04% of the portfolio, ranked #273.

Profund Advisors first reported a position in CVS in Q2 2013 and has held it in 53 quarters since. The position peaked at $6.13M in Q1 2015. 2,061 funds tracked by Wall St. Rank hold CVS as of Q2 2026.

  • Profund Advisors held 14,213 shares of CVS Health worth $1.47M as of Q2 2026.
  • Profund Advisors sold 3 CVS Health shares in Q2 2026, an estimated $268.
  • CVS Health made up 0.04% of Profund Advisors's portfolio in Q2 2026, its #273 holding.
  • Profund Advisors first reported a position in CVS Health in Q2 2013 and has held it in 53 quarters since.
  • Profund Advisors's CVS Health position peaked at $6.13M in Q1 2015.
  • 2,061 funds tracked by Wall St. Rank held CVS Health as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.